Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety.

Androgen deprivation therapy (ADT) using gonadotropin-releasing hormone agonist (s) (GnRH-A) remains the backbone of advanced prostate cancer treatment. In this review, we assessed the efficacy, safety, and convenience of administration of various GnRH-A. All GnRH-A (goserelin, triptorelin, buserelin, histrelin, and leuprorelin) have comparable potential to suppress testosterone (T) levels (≤50 ng/dL in a month and ≤20 ng/dL in 3 months). However, goserelin has shown better efficacy in maintaining T levels ≤50 ng/dL compared with leuprolide. The incidences of T escape are lower with goserelin and leuprolide than buserelin. Goserelin also has maximum benefit in prostate-specific antigen suppression. In neoadjuvant setting, when only goserelin was used, the 10-year overall survival (OS) rate was 42.6% to 86%. When either goserelin or leuprolide was used, the 10-year OS rate was 62%. As an adjuvant to radical prostatectomy, goserelin had a 10-year survival rate of 87%, and triptorelin had an 8-year survival rate of 84.6%. Goserelin further showed an absolute survival rate of 49% when used as an adjuvant to radiotherapy. The survival rates further improved when GnRH-A are used as combined androgen blockade compared with monotherapy. The frequency and severity of adverse events (hot flushes, fatigue, sexual dysfunction) are comparable among the GnRH-A. Goserelin appears to be the most convenient of all the GnRH-A for administration. Lack of conclusive comparative evidence makes it imperative to have a holistic approach of considering the patient profile and the disease characteristics to select the appropriate GnRH-A for ADT in prostate cancer.

Recurrent squamous cell carcinoma of the skin treated with immunotherapy.

Squamous cell carcinoma (SCC) has a good prognosis, while metastatic tumors have aggressive behavior. Immunotherapy has become a standard line of treatment in metastatic cancers; pembrolizumab has shown promising results and improved quality of life in recurrent and metastatic cancers. We report a case of recurrent SCC of the skin with extensive disease and a known case of human immunodeficiency virus. He completed standard lines of treatment and currently on immunotherapy. After 3 cycles of immunotherapy plus chemotherapy, he got a complete metabolic response. Our experience showed palliative benefits and increased quality of life.

Comparison of contralateral breast dose for various tangential field techniques in clinical radiotherapy.

Contralateral breast (CLB) cancer is a rare but serious concern in radiotherapy. In this study, the CLB dose was measured using MOSFET dosimeter in 49 patients who underwent breast conservation surgery treated by different radiotherapy tangential field techniques, which included enhanced dynamic wedge (EDW), physical wedge, and intensity modulated radiation therapy (IMRT). The mean percent of the prescribed dose received by the contralateral areola in treatment technique using physical wedge (Cobalt), physical wedge (Linac), EDW, and IMRT were 4.27% (SD: 0.65), 3.61% (SD: 0.60), 3.38% (SD: 0.58), and 1.65% (SD: 0.24), respectively. There was a 29% CLB dose reduction at 3 cm from the medial tangential field border with IMRT compared to other wedged tangential field techniques. The study shows that the CLB dose could be reduced with IMRT or reducing or avoiding the medial wedge in conventional tangential field planning for breast cancer.

A study on contralateral breast surface dose for various tangential field techniques and the impact of set-up error on this dose.

The risk of inducing contralateral breast (CLB) cancer in patients undergoing tangential field irradiation for the treatment of breast cancer is a serious concern in radiation oncology. A bilateral breast phantom made of wax attached onto the Alderson Rando phantom was used for studying the CLB dose for techniques using physical wedges, EDWs, IMRT and open fields. The skin dose to the CLB was measured at four different points (3 cm from the medial border of the tangential field (P1), nipple (P3), axilla (P4), midpoint between P3 and P1 (P2)). The highest measured dose occurred at P1 with the 60 degrees physical wedges; it was 15.3% of the dose at isocentre. Similarly, the dose measured at P3 (nipple) with 60 degrees physical wedges was 1.90 times higher than the dose with 60 degrees EDWs. The dose at P1 for IMRT (7.8%) was almost the same as that for the open field (8.7%). The skin dose measured at the nipple was 2.1 - 10.9 % of the isocentre dose. The highest CLB doses were contributed by medial wedged fields. The dose to the CLB can be reduced by using IMRT or avoiding wedging the medial tangential fields. A set-up error in the longitudinal direction has little impact on the CLB dose. Set-up errors > 1 cm in the vertical and lateral directions have significant impact on the CLB dose.

Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer.

BACKGROUND: Prostate cancer is biologically and clinically a heterogeneous disease that makes imaging evaluation challenging. One of the important challenges in this cancer is to detect recurrent disease. Biochemical response using Prostate Specific Antigen (PSA) and Imaging using several PET tracers have poor sensitivity and specificity. Therefore, we analyse the role of Ga68-PSMA (Prostate Specific Membrane Antigen) imaging in prostate cancer, which is a new PET tracer. METHODS: In this study, we evaluated PET scans of 262 patients with diagnosis of prostate cancer. These patients were scanned using Ga68-PSMA for either staging or response evaluation. RESULTS: 336 PSMA scans were performed. Ga68-PSMA scan resulted in the detection of extra-prostatic disease in 53.2% of cases when done at baseline before commencing any treatment. The sensitivity of Ga68-PSMA at baseline with histopathological diagnosis was 95% with 95% CI ranging from 86% to 98%. The positive predictive value was high at 98% with 95% CI ranging from 91% to 99%. In 26 (10%) patients who had surgical castration, Ga68-PSMA scan was able to detect disease progression / castration resistance in 100% of cases. The outcome of castration-resistant prostate cancer was compared with other cases where castration was not done. In those who did not undergo castration, there was a significantly better response by hormone therapy (p = 0.03) and radiotherapy (p = 0.01) on Ga68-PSMA. The sensitivity of Ga68-PSMA response with biochemical response was 66.7% with 95% CI ranging between 46 %- 82.7%. Ga68-PSMA response did not correlate with biochemical response. CONCLUSION: Ga68-PSMA has good sensitivity for diagnosis, staging, restaging, evaluation of therapy response and prognostication in prostate cancer.

Glioblastoma with signet ring cell morphology: A diagnostic challenge.

Glioblastoma (WHO Grade IV), the most frequent malignant brain tumor, can have varied morphologic variations like epithelial/glandular structures, granular cells, and lipidized cells. Glioblastoma with signet ring cell morphology is very unusual and can mimic a metastatic carcinoma. These rare tumors may be just a morphological variant or may signify a different carcinogenic pathway.

Cranio Spinal Irradiation of Medulloblastoma Using High Precision Techniques - A Dosimetric Comparison.

Radiotherapy planning, delivery and junction dose verification remain exigent for Cranio Spinal Irradiation (CSI) in medulloblastoma patients. This study aims to evaluate high precision techniques such as Intensity Modulated Radiation Therapy (IMRT), Rapid Arc Therapy (RA) with and without flattening filter (FF) on the basis of dosimetric analysis. Five patients treated with jagged junction Intensity Modulated RadioTherapy (IMRT) using dynamic Multi Leaf Collimators (MLC) were randomly selected for this retrospective study. IMRT, Rapid Arc (RA) plans were simulated in the same CT data set with and without flattening filter. Total dose prescribed was 28.80 Gy in 16 fractions. An evaluation criterion of 98% of PTV receiving 100% of the prescription dose was followed in all plans. Twenty treatment plans with 260 Dose Volume Histograms (DVHs) was created. Dosimetric parameters such as Dmax, Dmin, Dmean, V95%, V107%, CI for PTV and Dmax, Dmean, V80%, V50%, V30%, V10% for Organs At Risk (OAR) were extracted from DVHs. Treatment delivery efficiency was also evaluated for total Beam On Time (BOT). FFF Rapid Arc therapy : 6F_RA) resulted in conformal doses throughout the cranio spinal axis. FF and FFF dynamic IMRT had minimal V107%, 1.23% and 2.88% compared to 49.15 and 66.36 of rapid arc therapy (with and without FF). 6F_IMRT resulted in lesser mean doses to eyes, liver, lungs and kidneys. Heart mean dose was less (3.08 Gy) with 6X_IMRT. Thyroid and esophagus doses could be reduced to about 41.2% and 10% respectively with 6F_RA. The BOT for the treatment techniques were 3.43 min (6X_IMRT), 1.59 min (6F_IMRT), 5min (6X_RA), 4.5 min (6F_RA). Removal of flattening filter in IMRT could improve dose coverage along the caniospinal axis and normal tissue sparing. A reduction of 46.3% BOT could increase treatment efficiency of 6F_IMRT compared to 6X_IMRT. CSI could be simpler since junction doses can be evaded in IMRT and RA techniques.

Cranio Spinal Irradiation of Medulloblastoma Using High Precision Techniques - A Dosimetric Comparison.

Radiotherapy planning, delivery and junction dose verification remain exigent for Cranio Spinal Irradiation (CSI) in medulloblastoma patients. This study aims to evaluate high precision techniques such as Intensity Modulated Radiation Therapy (IMRT), Rapid Arc Therapy (RA) with and without flattening filter (FF) on the basis of dosimetric analysis. Five patients treated with jagged junction Intensity Modulated RadioTherapy (IMRT) using dynamic Multi Leaf Collimators (MLC) were randomly selected for this retrospective study. IMRT, Rapid Arc (RA) plans were simulated in the same CT data set with and without flattening filter. Total dose prescribed was 28.80 Gy in 16 fractions. An evaluation criterion of 98% of PTV receiving 100% of the prescription dose was followed in all plans. Twenty treatment plans with 260 Dose Volume Histograms (DVHs) was created. Dosimetric parameters such as Dmax, Dmin, Dmean, V95%, V107%, CI for PTV and Dmax, Dmean, V80%, V50%, V30%, V10% for Organs At Risk (OAR) were extracted from DVHs. Treatment delivery efficiency was also evaluated for total Beam On Time (BOT). FFF Rapid Arc therapy (6F_RA) resulted in conformal doses throughout the cranio spinal axis. FF and FFF dynamic IMRT had minimal V107%, 1.23% and 2.88% compared to 49.15 and 66.36 of rapid arc therapy (with and without FF). 6F_IMRT resulted in lesser mean doses to eyes, liver, lungs and kidneys. Heart mean dose was less (3.08 Gy) with 6X_IMRT. Thyroid and esophagus doses could be reduced to about 41.2% and 10% respectively with 6F_RA. The BOT for the treatment techniques were 3.43 min (6X_IMRT), 1.59 min (6F_IMRT), 5min (6X_RA), 4.5 min (6F_RA). Removal of flattening filter in IMRT could improve dose coverage along the caniospinal axis and normal tissue sparing. A reduction of 46.3% BOT could increase treatment efficiency of 6F_IMRT compared to 6X_IMRT. CSI could be simpler since junction doses can be evaded in IMRT and RA techniques.

PET/CT guidance for percutaneous fine needle aspiration cytology/biopsy.

PET/CT, used as a guiding tool, can improve the accuracy of percutaneous fine needle aspiration cytology (FNAC)/biopsy due to its ability to incorporate both physiological and anatomical information.

A simple technique for cranio-spinal irradiation in pediatric patients.

PURPOSE: Field matching poses challenges in craniospinal irradiation (CSI) as it leads either to underdosage or overdosage in the junctional area. A simple technique for CSI in pediatric patients is proposed. MATERIALS AND METHODS: Computed tomography scans were performed in the prone position. Two lateral cranial fields and a direct posterior spinal field were planned with a common central axis. Half-beam-blocked cranial fields with zero collimator rotation were used for treating the cranium. A half-beam-blocked field defined with jaws was used to treat the spinal column at an extended source-to-surface distance. Before treating the patient, matching of the cranial and spinal field junction along the central axis was verified with an extended dose range film. RESULTS AND CONCLUSION: The technique described is simple and easy to implement and can be applied to pediatric patients undergoing CSI. This method has the potential to reduce daily setup time and setup errors. This technique is ideally suitable for patients with spinal fields less than 30 cm.